Hansoh's Inebilizumab Gains First Global Approval for IgG4-RD in China

Hansoh Pharmaceutical has secured approval in its China homeland for CD19 inhibitor inebilizumab in immunoglobulin G4-related disease (IgG4-RD), following positive Phase III MITIGATE trial results showing 87% reduction in disease flare risk versus placebo. The monoclonal antibody (mAb) previously gained approval for neuromyelitis optica spectrum disorder (NMOSD) in 2022. Hansoh licensed Chinese rights from Viela Bio in 2019 before its acquisition by Horizon Therapeutics and subsequently Amgen.

The randomised 160-patient trial demonstrated significant improvement in time to disease flare (HR=0.13) and all key secondary endpoints including complete remission rates. IgG4-RD affects approximately 1 to 5 per 100,000 people, causing progressive multi-organ fibrosis through CD19-positive B-cell mediated inflammation. Inebilizumab joins only one other candidate in Phase III development for this rare autoimmune condition, positioning Hansoh as the leader in this niche therapeutic area.

PharmCube's NextBiopharm® database shows that inebilizumab has consistently led the anti-CD19 mAb race, which includes a total of 9 active programs. Click here to request a free trial for NextBiopharm®.

Daily News
CARsgen's CAR-T Gains First Solid Tumour Approval Globally
2026-06-24
TrueLab, Bionyra Announce USD 985mn Multi‑Asset Licensing Deal
2026-06-24
Antengene Out‑Licenses Second TCE to K2 Therapeutics in Near‑USD 1bn Deal
2026-06-23
Insilico, SK Biopharma Announce AI‑Driven Drug Discovery Partnership
2026-06-23
Westlake Closes RMB 100mn+ Round for Red Blood Cell Drug Platform
2026-06-22
Latest Report
TOP-25 Drug Targets
Details